Clinical Study of a Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Latest Information Update: 23 Nov 2021
At a glance
- Drugs INeo Vac P01 (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 15 Nov 2021 Status changed from not yet recruiting to recruiting.
- 25 Mar 2021 New trial record